Toys and technology for rehabilitation in cerebral pals... (ichols B.I.D. professor of industrial de...)

Toys and technology for rehabilitation in cerebral palsy patients

Date:7/1/2008

ichols, B.I.D., professor of industrial design at RISD, and in the fall of 2006, the students in Crisco's class were challenged to design therapeutic toys. At the end of the course they then applied to the Rhode Island Science and Advisory Technology Council (STAC) and obtained a grant providing additional funding for the project. Specifically, they were hoping to develop toy controls for games that would rely on the use of the wrist and forearms for children with CP who lack the fine motor skills normally required of hand-held game controllers. The team collaborated with Susan D'Andrea, Ph.D., of Afferent Corporation, David Durfee, Ph.D., of Bay Computer Associates to further develop the ideas born out of the students' assignment, and then worked with Cornerstone Prototype Development.

Crisco says, "There were a lot of design iterations, but in the end, there were about 15 prototypes and concepts that came out of the class." The efforts were then focused on designing a hand-held control that could be used by the CP patients as both fun and therapeutic and would increase the use of the affected limb, helping to strengthen the muscles. At the same time, the researchers wanted to be able to obtain information from the use of the toys. So the controls are equipped with data logging capabilities that allow the researchers to study the extent of use and the arm movements and also measure the outcome.

The project has now reached its study phase, during which 20 children with CP between ages 5 and 12 will be enrolled. Each child in the study will be provided with a toy to be used at home as part of their normal play. Once a month, their progress will be charted, looking at markers for functional gain.

"We are proud to be able to support the innovative work done by Hasbro Children's Hospital to develop interactive toys that can actually serve as rehabilitative therapy for children with cerebral palsy," said Eileen Howard Dunn, Vice President,
'/>"/>

Contact: Nancy Cawley
ncawley@lifespan.org
Lifespan
Source:Eurekalert

3

GOOD

Page: 1 2 3
Related medicine news :

1. Flaws in the barcoded technology used to reduce medication administration errors identified
2. New technology may help Olympic sailing
3. Sacred Technology Delivers Divine Medicine Online
4. MAP Pharmaceuticals Acquires Proprietary Drug Particle Formulation Technology From Eiffel/Telesso Technologies Limited
5. June 2008 Mayo Clinic Health Letter Highlights New MRI Scanning Technology, Obesity-Related Cancer, and Do-It-Yourself Massage
6. Londons Royal Brompton Hospital Opens New Electrophysiology Lab With State of the Art Magnetic Technology to Treat Arrhythmias
7. Nerites Technology Wins Scientific Accolades
8. ONR offers up to $1M for innovative science and technology ideas
9. Revolutionary Therapy: Needle-Free Technology for the Treatment Of Blinding Eye Disease
10. Plexus Online Enables Business-Government-Academic Collaboration for Advanced Technology Institute
11. China Sky One Medical, Inc. Research Center Recognized by Heilongjiang Science and Technology Institute

Post Your Comments:

(Date:3/12/2010)... calls for ,black box, warning to alert those who ... News) -- The anti-clotting drug Plavix must now carry ... and doctors that some people don,t metabolize the medication ... a certain genetic variation can,t convert the blood thinner ... for heart attack and stroke, the U.S. Food and ...

(Date:3/12/2010)... , March 12 Haven Behavioral War Heroes Hospital ( ... disorder (PTSD); co-occurring chemical dependency disorders, depression, mood, anxiety, psychotic and adjustment disorders ... inpatient facility located within St. Mary Corwin Hospital in Pueblo, Colo. ... ... ...

(Date:3/12/2010)... into a solid, profitable and industry-leading corporation, LIMU, based in Florida , ... and expansion initiatives, LIMU will unveil a preview of the LIMU 2K10 campaign ... Dallas, Texas . , ... ... , ...

(Date:3/12/2010)... return to their normal state of mind soon after ... (HealthDay News) -- No matter how cheerful you felt ... that secluded beach, no matter how thrilled you were ... vacation bliss won,t last long. , Sadly, new research ... soon after they get home to the pile of ...

(Date:3/12/2010)... new Medicare supplement (Medigap) plans M & N will take effect. ... seen with Medicare supplements. Precision Senior Marketing, a national Medicare FMO, ... new Medicare Supplement Plan N. , ... Austin, TX ... Medicare FMO, announced today that it is providing rates and information ...

Breaking Medicine News(10 mins):Health News:Plavix Less Effective in Some Patients 2 Health News:Plavix Less Effective in Some Patients 3 Health News:Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members 2 Health News:Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members 3 Health News:Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members 4 Health News:LIMU Accelerates Growth Era With Brand Transformation 2 Health News:LIMU Accelerates Growth Era With Brand Transformation 3 Health News:Happy From Your Vacation? It Won't Last 2 Health News:Happy From Your Vacation? It Won't Last 3 Health News:Medicare Supplement Plan N Information and Rates Now Available Through Precision Senior Marketing 2

[0] Plavix Less Effective in Some Patients [0] Haven Behavioral War Heroes Hospital to Offer Comprehensive Psychiatric Treatment for Military Service Members [0] LIMU Accelerates Growth Era With Brand Transformation [0] Happy From Your Vacation? It Won't Last [0] Medicare Supplement Plan N Information and Rates Now Available Through Precision Senior Marketing

... Pistorius files appeal challenging International Association of Athletics Federation ... ... LONDON, Feb. 13 Oscar Pistorius -- a double amputee,athlete from ... today initiated an appeal before the Court of Arbitration for Sport,(CAS) ...

... 2008 The Elsevier Foundation has announced today that it ... institutions from around the world in support of initiatives that ... and medicine. The recipient programs were selected from over 150 ... the developing world and the academic workplace. , ...

... with glasses brought them up to snuff with ... News) -- Preschoolers with poor vision significantly improved ... wearing prescription glasses, a new study shows. , ... have early vision problems that are undiagnosed and ...

... a leading,provider of electronic payment solutions to the ... audit as a Payment Card,Industry (PCI) Level 1 ... are critical in an era when the Federal,Reserve ... 2/3rds,of all U.S. non-cash payments. The Payment Card ...

... ... - 85% Gross Profit ... Prior Year, CHICAGO, Feb. 13 The Female Health Company,(Amex: FHC ), which ... first quarter of,FY2008., For the three months ended December 31, 2007, the Company,s net,revenues ...

... for Continued Growth, CAMBRIDGE, Mass., Feb. 13 Genzyme Corporation,(Nasdaq: ... and,fourth quarter of 2007 and provided an outlook for continued strong ... revenue in 2007 increased 20 percent to $3.8 billion from $3.2 ... broadly driven by growth across all segments ...

Oscar Pistorius Aims to Compete on Level Playing Field at 2008 Beijing Olympics Elsevier Foundation announces grants for innovative libraries and new scholars Fixing Poor Vision Boosts Preschoolers' Test Scores Vanco Services Completes Annual Security Assessment The Female Health Company Reports 37% Revenue Growth and Record Profits for First Quarter of FY2008 Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year

(Date:3/11/2010)... -- With obesity in America reaching alarming levels -- across our adult and youth populations ... BodyMedia,s wearable body-monitoring technology either in conjunction with a group weight loss program or as ... more weight than individuals who attempted to battle the bulge solo. ... ... ...

(Date:3/11/2010)... The U.S. Food and Drug Administration ... drug application (sNDA) of a new six-month 45-mg ... Depot (leuprolide acetate for depot suspension) ... prostate cancer. Palliative treatment helps to relieve symptoms ... by suppressing the production of the hormone testosterone. ...

(Date:3/11/2010)... On March 10-11, 2010 , the Joint Advisory Committees ... and the Drug Safety and Risk Management Advisory Committees -- discussed the design ... SYMBICORT ® (budesonide/formoterol fumarate dihydrate). , ... ... ...

Breaking Medicine Technology:The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 2 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 3 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 4 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 5 The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight 6 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 2 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 3 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 4 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 5 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 6 Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer 7 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 2 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 3 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 4 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 5 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 6 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 7 AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma 8 Unraveling kidney cancer 64184 1 Unraveling kidney cancer 64184 2 Unraveling kidney cancer 64184 3 Canine compulsive disorder gene identified in dogs 11339 1 Canine compulsive disorder gene identified in dogs 11339 2 Canine compulsive disorder gene identified in dogs 11339 3 Team finds link between stomach cancer bug and cancer promoting factor 11334 1 Team finds link between stomach cancer bug and cancer promoting factor 11334 2 Team finds link between stomach cancer bug and cancer promoting factor 11334 3

[0] The Results are in: Users of BodyMedia's Wearable Body-Monitoring Technology Lose 3 Times More Weight [0] Abbott Seeks FDA Approval of a New Six-Month 45-mg Formulation of Lupron(R) Depot for the Palliative Treatment of Advanced Prostate Cancer [0] AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma

... SAN MATEO, Calif., June 10 /PRNewswire-FirstCall/ - NeurogesX, ... on developing and,commercializing novel pain management therapies, announced ... lead product candidate, NGX-4010, in the,journal Neurology. The ... Treatment of Painful HIV,Neuropathy," will appear in the ...

... a 24-week multi-center, randomized, open-label study presented ... ... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) today announced data showing ... therapy for 24,weeks resulted in more patients achieving diabetes treatment goals ...

Other Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2 NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4 Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5

NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin

... (GH) is a monomeric protein produced and ... gland. GH is released from the pituitary ... under the regulatory control of hypothalamic somatostatin ... timing and frequency of GH release appears ...

... Cortisol is the most potent ... cortex. In plasma, most cortisol is ... globulin (CBG), with the remainder loosely ... specific intracellular receptors with effects in ...

... factor I (IGF-I or somatomedin C) is a ... It acts as a potent mitogen of cellular ... cell-surface receptors. In the circulation, IGF-I is bound ... the actions of IGF-I by modulating the interaction ...

... (PSA) derives its name from its first ... The majority of PSA circulates bound ... Serum concentrations of PSA are elevated in ... (BPH) and prostatitis [1-3]. In addition, PSA ...

Medicine Products:

hGH, Ultra-Sensitive ELISA Test Cortisol RIA Test IGF-I IRMA Test (Non-Extraction)Total PSA IRMA Test

Toys and technology for rehabilitation in cerebral pals...(ichols B.I.D. professor of industrial de...),Health